在可切除非小细胞肺癌中,基于免疫治疗的新辅助疗法的现实结果
Jie Shen1, Linping Gu1, Yuwen Qi1
1Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Frontiers in immunology
|October 11, 2023
概括
与单独的化疗相比,新辅助免疫疗法在可切除的非小细胞肺癌 (NSCLC) 中显著改善了主要病理反应. 这种方法是安全的,不会增加不良事件或复杂化手术.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 新辅助疗法越来越多地用于可切除的非小细胞肺癌 (NSCLC).
- 免疫疗法在改善NSCLC病理反应方面表现有前途.
- 评估新辅助免疫疗法的有效性和安全性至关重要.
研究的目的:
- 在可切除的NSCLC患者中,与化疗相比,研究新辅助免疫疗法的有效性和安全性.
- 评估结果,包括主要病理反应 (MPR),完整的病理反应 (pCR) 和生存率.
主要方法:
- 一项开放的,双臂的观察性研究,涉及51名可切除NSCLC的患者.
- 患者接受了新辅助免疫疗法或新辅助化疗,随后进行了手术切除.
- 主要终点是MPR;次要终点包括pCR,放射性反应,无事件生存 (EFS) 和整体生存 (OS).
主要成果:
- 新辅助免疫疗法在41.9%的患者中实现了MPR,而化学疗法为15.0% (P=0.043).
- 免疫疗法的病理完整反应率为19.4%,化学疗法为5% (P=0.223).
- 放射性反应率分别为71%和60%,在28个月的中位随访期内,EFS或OS没有显著差异.
结论:
- 新辅助免疫疗法在可切除NSCLC的MPR中比单独的化疗提供了显著的优势.
- 免疫疗法没有增加不良事件或阻碍手术切除.
- 新辅助免疫疗法是切除性NSCLC的有效和安全的治疗选择.
相关概念视频
01:27Tumor Immunotherapy
539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K